Parkinson’s Disease - Metabolic Networks and the Cognitive Treatment Response in Parkinson’s Disease
Protocol ID
Protocol Description
Cognitive deficits and behavioral abnormalities are well documented symptoms of Parkinson’s disease (PD). Furthermore, existing medications for the treatment of motor symptoms of PD can alter cognitive functioning and lead to behavioral side effects. This research study will used advanced imaging methods to study how PD alters brain regions involved in cognition and how current treatments for the disease affect these same regions. We hope that this research project will ultimately help physicians to individualize treatment for the growing number of patients with PD and cognitive difficulties, and to help guide the choice of medication to minimize behavioral side effects.
We will measure brain function with imaging methods (Positron Emission Tomography – PET scanning), neurological examinations, and neuropsychological testing.
Eligibility Criteria
• Group 1: PD patients who are about to begin taking levodopa as part of standard of care and PD patients who are about to begin taking ropinirole as part of standard of care
• Group 2: PD patients who are already taking medication for their PD symptoms as part of standard of care
• Group 3: Healthy volunteers
Primary Investigator(s)
- David Eidelberg, MD